You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
PREFAB MODULAR LIQUID-COOLED MICRO DATA CENTER
SBC: Flexnode Inc Topic: 1"To enable the future needs of efficient computing for edge data centers, Flexnode and its partners, the University of Maryland (UMD), Boeing, Iceotope, SHoP Architects, and Arup, propose to develop a prefabricated modular micro data center with unprecedented energy efficiency and power density. The proposed system leverages four key component and system-level technology advancements: (a) a novel, ...
STTR Phase I 2024 Department of EnergyARPA-E -
PREFAB MODULAR LIQUID-COOLED MICRO DATA CENTER
SBC: Flexnode Inc Topic: 1"To enable the future needs of efficient computing for edge data centers, Flexnode and its partners, the University of Maryland (UMD), Boeing, Iceotope, SHoP Architects, and Arup, propose to develop a prefabricated modular micro data center with unprecedented energy efficiency and power density. The proposed system leverages four key component and system-level technology advancements: (a) a novel, ...
STTR Phase II 2024 Department of EnergyARPA-E -
PREFAB MODULAR LIQUID-COOLED MICRO DATA CENTER
SBC: Flexnode Inc Topic: 1"To enable the future needs of efficient computing for edge data centers, Flexnode and its partners, the University of Maryland (UMD), Boeing, Iceotope, SHoP Architects, and Arup, propose to develop a prefabricated modular micro data center with unprecedented energy efficiency and power density. The proposed system leverages four key component and system-level technology advancements: (a) a novel, ...
STTR Phase II 2024 Department of EnergyARPA-E -
ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)
SBC: EMOCHA MOBILE HEALTH INC. Topic: NHLBISummary/Abstract: Sickle cell disease (SCD) is a severe inherited blood disorder that leads to frequent acute and costly long-term complications. Hydroxyurea is the primary SCD modifying medication in childhood because studies show that it can reduce acute complications and mitigate costly long-term comorbidities. Hydroxyurea non-adherence is common, however, and a key reason for the limited impac ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Highly Multiplexed Single Molecule Tethering
SBC: SCANOGEN INC. Topic: NIAIDHighly Multiplexed Single Molecule Tethering Summary Bloodstream infections in patients with sepsis symptoms should be promptly treated with antibiotics; however, the time required to identify pathogens using methods based on blood culture is a major obstacle to timely effective antimicrobial therapy. The development of a comprehensive molecular assay capable of identifying microbes directly from ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program
SBC: EMOCHA MOBILE HEALTH INC. Topic: NIDAPROJECT SUMMARY The COVID-19 pandemic intersecting with the opioid epidemic led to dramatic shifts in the delivery of care for opioid use disorders (OUD). Historically, methadone has been provided as directly-observed therapy (DOT) at opioid treatment programs (OTPs). This model of care delivery has been a barrier to accessing care due to imposed travel burden and disruption to work and family res ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CardioWatch: An Omics-Based Prediction Assay for Cardiac Late Effects ofAcute Radiation
SBC: NELSON SCIENTIFIC LABS LLC Topic: NIAIDConcerted efforts have led to the development of medical countermeasures against acute radiation toxicity in victims of a radiological accident or nuclear terrorism, thereby significantly increasing the chance of survival if such a radiological event were to occur today. However, survivors of acute radiation toxicities may develop delayed injuries that become clinically apparent months to years af ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of PTLS-209 for treatment for giardiasis
SBC: PRIMETIME LIFE SCIENCES, LLC Topic: NIAIDProject Summary: This project focuses on the development of treatment to combat giardiasis resistance to standard care drugs. Giardia lamblia is a highly infective waterborne parasite that causes severe diarrhea. Current antigiardiasis drugs fail in about 20% of cases, and they all have undesirable side effects. Additionally, drug-resistant G. lamblia strains can be readily raised in the laborator ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute
SBC: KaloCyte Inc Topic: NHLBIResearch Summary/Abstract ErythroMer (EM) is a novel biosynthetic blood substitute developed to address the critically unmet need for emergency transfusion in situations where the use of banked red blood cells (RBCs) are either not available or undesirable. EM is a self-assembled lipid-oligomeric hybrid nanoparticle with a high per particle payload of hemoglobin (Hb) and the allosteric modifier, R ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health